SBI Securities’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

SBI Securities’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-218	Closed	-$244	–	4198
2025 Q2	$244	Sell	218 -2	-0.9%	-$2	﹤0.01%	3251
2025 Q1	$277	Buy	220 +53	+32%	+$94	﹤0.01%	3102
2024 Q4	$379	Buy	+167	New	+$308	﹤0.01%	2997

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

SBI Securities's BCLI Position: Q3 2025 in Review

SBI Securities sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 218 shares — an estimated $244 sold.

SBI Securities first reported a position in BCLI in Q4 2024 and held it in 3 quarters. The position peaked at $379 in Q4 2024. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

SBI Securities reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
SBI Securities sold 218 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $244.
SBI Securities first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2024 and held it in 3 quarters.
SBI Securities's BRAINSTORM CELL THERAPUTC position peaked at $379 in Q4 2024.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.